TCM Biotech Int’l (TCM Biotech Biotech) is set to hold its pre-listing performance briefing by March 9, with an official IPO expected in early April at a tentative price of NT$132 per share.

• Dual-Track Strategy: Chairman Hsu Huan-ching highlighted the company’s "Operations & R&D Parallel" strategy. Currently, 90% of revenue is derived from established pharmaceutical and medical device sales across bone, urology, and OB/GYN departments, providing a stable cash flow to fund high-risk innovation.
• The U101 Breakthrough: General Manager Wang Ya-chun introduced U101, the world's first non-antibiotic oral drug for preventing Recurrent Urinary Tract Infection (rUTI). The drug is currently in a Phase III pivotal trial in Taiwan, with interim analysis results expected in Q3 2026. With a global potential patient base of 100 million, U101 aims to solve the problem of antibiotic resistance in chronic UTI patients.
• Precision Liver Care: TCM Biotech’s CATCHIMERA platform has received LDTs certification in Taiwan. Using HBV-chimeric DNA as a biomarker, it offers 83.3% sensitivity for monitoring post-operative liver cancer recurrence. The company has applied for US FDA Breakthrough Device Designation (BDP) and is eyeing the 70-million-strong HBV carrier market in China.

Resource: 泰宗132元掛牌上市倒數　反覆性泌尿道感染新藥估Q3期中分析